TARE FOR CHOLANGIOCARCINOMA AND
NEUROENDOCRINE TUMOUR LIVER METASTASES
Evidence and clinical context for Y-90 radioembolization in two important non-HCC liver tumour indications โ intrahepatic cholangiocarcinoma (iCCA) and neuroendocrine tumour liver metastases โ where TARE provides disease control not achievable by systemic therapy alone.
analyticsAt a Glance
- check_circleiCCA: TARE provides locoregional control in unresectable disease โ Phase II data shows objective response rates of 25โ45%
- check_circleNET liver metastases: TARE achieves tumour volume reduction and symptom control in somatostatin-refractory patients
- check_circleBoth indications are established uses of Y-90 at specialist centres โ not experimental
- check_circleCancerFax coordinates TARE for iCCA and NET at specialist interventional oncology centres in China
TARE Beyond HCC โ Two Important Expanding Indications
While HCC and colorectal liver metastases represent the largest evidence bases for Y-90 radioembolization, two other liver tumour types have accumulating clinical data supporting TARE as a meaningful treatment option: intrahepatic cholangiocarcinoma (iCCA) and neuroendocrine tumour (NET) liver metastases. Both benefit from TARE's capacity to treat multiple liver lesions simultaneously with a single transarterial session.
โiCCA and NET liver metastases are the two most clinically established TARE indications beyond HCC and CRLM โ and both have specialist centres in China with active experience.โ
Intrahepatic Cholangiocarcinoma (iCCA)
iCCA arises from the intrahepatic bile duct epithelium and is typically diagnosed at an advanced, unresectable stage. It is poorly responsive to chemotherapy, highly infiltrative, and historically offered limited locoregional treatment options. TARE provides an additional liver-directed approach in this difficult indication.
NET Liver Metastases
Neuroendocrine tumours frequently metastasise to the liver โ and the liver is often the dominant determinant of both survival and symptom burden (hormonal symptoms from functioning NETs). When somatostatin analogues and PRRT are not options or have failed, TARE provides effective locoregional disease control.
Clinical Evidence: TARE in iCCA and NET Liver Metastases
Published efficacy data from Phase II trials and cohort studies of Y-90 radioembolization in intrahepatic cholangiocarcinoma and NET liver metastases.
TARE in Intrahepatic Cholangiocarcinoma โ ORR and OS
Objective response rates (mRECIST) and median OS from Phase II trial and retrospective cohort data in unresectable iCCA. Source: Edeline et al., Lancet Gastroenterol 2020; pooled retrospective series.
- ORR: TheraSphere (iCCA, Phase II)~25โ40%
- Median OS: TARE (iCCA)~12โ14 months
- Median OS: gemcitabine-cisplatin (reference)~11.7 months
TARE in NET Liver Metastases โ Objective Response and Symptom Control
Tumour response rate and hormonal symptom control with SIR-Spheres or TheraSphere in NET liver metastases. Source: Kennedy et al., JCO 2008; multiple retrospective series.
- Objective response rate (NET liver mets, TARE)~60โ90%
- Symptom control (functioning NET)~80โ90%
TARE in Intrahepatic Cholangiocarcinoma โ Eligibility Reference
Patient selection criteria for TARE in iCCA โ based on Phase II trial eligibility criteria and published expert centre practice.
| Selection Factor | Favourable for TARE | Requires Assessment | Contraindicated |
|---|---|---|---|
| Resectability | Unresectable (primary indication) | Borderline resectable โ TARE as downstaging | Resectable โ surgery preferred |
| Liver function | Child-Pugh A, adequate biliary drainage | Biliary obstruction needing drainage first | Liver failure; uncontrolled biliary sepsis |
| Disease distribution | Predominantly hepatic disease | Liver-dominant with limited extrahepatic | Extensive extrahepatic disease limiting prognosis |
| Prior treatment | Gemcitabine + cisplatin failure/intolerance | First-line concurrent with chemotherapy | N/A โ TARE can be used at any line |
| Lung shunt fraction | < 10% | 10โ20% with activity reduction | > 20% |
| ECOG PS | 0โ1 | 2 | 3โ4 |
TARE in iCCA vs TARE in NET Liver Metastases โ Different Clinical Goals
The rationale and therapeutic goals for TARE differ significantly between these two indications โ understanding the goal shapes expectations and patient selection.
TARE in Intrahepatic CCA (iCCA)
- Primary goal: locoregional disease controliCCA is poorly chemosensitive โ TARE provides a locoregional treatment option to control hepatic disease progression in patients where systemic therapy has failed or is poorly tolerated.
- Downstaging potentialA minority of iCCA patients achieve sufficient tumour response with TARE to become eligible for surgical resection or liver transplantation โ a high-value outcome in an otherwise incurable disease.
- Combination with systemic therapyTARE combined with gemcitabine + cisplatin or with IDH1 inhibitors (ivosidenib) or FGFR2 inhibitors (pemigatinib) is being explored in active trials โ potentially providing synergistic locoregional and systemic control.
- Expected ORR: ~25โ40%Lower than HCC and NET but clinically meaningful in a disease where standard chemotherapy ORR is ~26%. Stable disease as best response still delays progression.
TARE in NET Liver Metastases
- Primary goal: tumour volume reduction and symptom controlNET liver metastases cause two problems: liver bulk (and eventual hepatic failure) and hormonal excess (carcinoid syndrome, VIPoma symptoms). TARE addresses both simultaneously.
- Exceptional response ratesNET liver metastases are typically hypervascular โ microspheres distribute preferentially into tumour-feeding vessels and the radiation effect on slowly dividing NET cells is especially durable.
- Symptom management in functioning NETsFor carcinoid syndrome, VIPoma, glucagonoma, and other hormone-secreting NETs, TARE reduces tumour volume and hormonal secretion โ achieving symptom control in up to 80โ90% of treated patients.
- TARE after PRRT failurePeptide receptor radionuclide therapy (PRRT with lutetium-177 DOTATATE) is now first-line for somatostatin receptor-positive NETs โ TARE is increasingly used in patients who have progressed after PRRT.
TARE in iCCA and NET โ Key Numbers
The most clinically relevant outcome figures for TARE in these two indications.
- ~25โ40%ORR with TARE in unresectable intrahepatic cholangiocarcinomaA meaningful response rate in a disease where standard chemotherapy produces ~26% ORR โ and where most locoregional therapies were previously unavailable.
- ~80โ90%Symptom control rate with TARE in functioning NET liver metastasesExceptional hormonal symptom control โ particularly for carcinoid syndrome โ making TARE a highly effective palliative tool for functioning NET.
- ~60โ90%Objective response rate (any degree) in NET liver metastasesThe highest TARE response rate of any liver tumour indication โ reflecting NET's hypervascular nature and radiosensitivity.
More from the TARE / Y-90 Resource Library
Continue exploring Y-90 radioembolization โ from the HCC evidence base and CRLM trials to treatment day and safety.
Frequently Asked Questions: TARE for iCCA and NET
Is TARE approved specifically for cholangiocarcinoma?
TheraSphere has FDA Humanitarian Device Exemption (HDE) approval for unresectable HCC and for liver tumours including metastases โ this broadly covers iCCA. SIR-Spheres has FDA PMA approval specifically for colorectal liver metastases but is used off-label for iCCA and NETs based on clinical evidence and institutional experience. Both products have CE mark in Europe and NMPA approval in China โ usage for iCCA and NET is established clinical practice at specialist centres, not experimental. CancerFax identifies Chinese centres with specific iCCA and NET TARE experience.
Can TARE be used alongside FGFR2 inhibitors (pemigatinib, futibatinib) for FGFR2-fusion iCCA?
This is an area of active investigation. The combination of TARE (locoregional hepatic control) with FGFR2 inhibitors (systemic targeted therapy) is biologically compelling โ TARE provides cytoreduction that could be complementary to FGFR2-targeted cell death. Formal trial data is limited, but retrospective case series at expert centres suggest the combination is tolerable. CancerFax can identify Chinese centres currently combining TARE with FGFR2-targeted therapy for iCCA within or outside a clinical trial framework.
My NET has already been treated with PRRT (lutetium-177). Can I still receive TARE?
Yes โ TARE after PRRT failure (or in patients not eligible for PRRT due to insufficient somatostatin receptor expression) is a clinically established approach. The radiation mechanisms are completely different: PRRT uses alpha/beta particles delivered via somatostatin receptor targeting, while TARE uses hepatic artery-delivered beta radiation โ they operate through non-overlapping pathways and prior PRRT does not preclude TARE. The key eligibility considerations are the same as for any TARE patient: preserved liver function, acceptable lung shunt fraction at mapping, and hepatic tumour burden that can be meaningfully targeted.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is TARE an Option for Your Cholangiocarcinoma or NET Liver Metastases?
CancerFax reviews your iCCA or NET records โ histology, liver tumour burden, systemic therapy history, and liver function โ to assess TARE eligibility at specialist interventional oncology centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.